Sugi Predict

Sugi Predict / Compounds / SCHEMBL783668

SCHEMBL783668

SCHEMBL783668

O=C1CCc2c(F)ccc(F)c21

nearest known ligand 0.41

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ GLA P06280 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ PTGS1 P23219 2/20 0.33
▸ PTGS2 P35354 2/20 0.33
▸ CHEK1 O14757 1/20 0.33
▸ SRD5A1 P18405 1/20 0.33
▸ EPAS1 Q99814 1/20 0.32
▸ TYMS P04818 1/20 0.32
▸ NOTUM Q6P988 1/20 0.31
▸ HSD17B1 P14061 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29605666 1.00 KDM4E (0.41) KDM4EALDH1A1GLAGAAHPGD
SCHEMBL1477849 0.86 ALDH1A1 (0.41) KDM4EALDH1A1GAA
SCHEMBL8237233 0.86 ALDH1A1 (0.41) ALDH1A1
SCHEMBL29525031 0.86 ALDH1A1 (0.41) KDM4EALDH1A1GAA
SCHEMBL5763704 0.83 HSD17B1 (0.40) KDM4EALDH1A1GLAGAAHPGD
SCHEMBL15276007 0.83 KDM4E (0.40) KDM4EALDH1A1GLAGAAHPGD
SCHEMBL16290332 0.83 KDM4E (0.36) KDM4EALDH1A1GLAGAAHPGD
SCHEMBL12261417 0.83 KDM4E (0.56) KDM4EALDH1A1GLAGAAHPGD
SCHEMBL14430310 0.83 KDM4E (0.47) KDM4EALDH1A1GLAGAAHPGD
SCHEMBL30067439 0.83 KDM4E (0.40) KDM4EALDH1A1GLAGAAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12617880-B2 Compounds for use in catalyst compositions for the production of polyolefins SABIC GLOBAL TECHNOLOGIES B.V. (NL) 2026-05-05 — — US disclosed
US-20250136582-A1 SELECT KRAS G12C INHIBITORS AND USES THEREOF 1200 PHARMA LLC (US) 2025-05-01 — — US disclosed
US-20240254140-A1 COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION HOFFMANN-LA ROCHE INC. (US) 2024-08-01 — — US disclosed
CN-114364707-B Compounds in catalyst compositions for the production of polyolefins SABIC环球技术有限责任公司 2023-09-19 — — CN disclosed
WO-2023041756-A1 NEW COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION F. HOFFMANN-LA ROCHE AG (CH) 2023-03-23 — — WO disclosed
US-20220332861-A1 COMPOUNDS FOR USE IN CATALYST COMPOSITIONS FOR THE PRODUCTION OF POLYOLEFINS SABIC GLOBAL TECHNOLOGIES B.V. (NL) 2022-10-20 — — US disclosed
EP-4028437-A1 COMPOUNDS FOR USE IN CATALYST COMPOSITIONS FOR THE PRODUCTION OF POLYOLEFINS SABIC Global Technologies, B.V. (NL) 2022-07-20 — — EP disclosed
CN-114364707-A Compounds for use in catalyst compositions for the production of polyolefins SABIC环球技术有限责任公司 2022-04-15 — — CN disclosed
WO-2021048030-A1 COMPOUNDS FOR USE IN CATALYST COMPOSITIONS FOR THE PRODUCTION OF POLYOLEFINS SABIC GLOBAL TECHNOLOGIES B.V. (NL) 2021-03-18 — — WO disclosed
CN-103923021-B It is suitable for the heteroaryl compound of E1 activating enzyme inhibitors 米伦纽姆医药公司 2018-03-30 — — CN disclosed
WO-2008019124-A1 HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF E1 ACTIVATING ENZYMES MILLENNIUM PHARMACEUTICALS, INC. (US) 2008-02-14 — — WO disclosed
EP-1701942-A1 NON-NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS MEDIVIR AB (SE) 2006-09-20 — — EP disclosed
US-20060167055-A1 Non-nucleoside reverse transcriptase inhibitors MEDIVIR AB (SE) 2006-07-27 — — US disclosed
WO-2005066131-A1 NON-NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS MEDIVIR AB (SE) 2005-07-21 — — WO disclosed
EP-1534276-A2 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MEDIVIR AB (SE) 2005-06-01 — — EP disclosed
EP-1423368-A1 UREA AND THIOUREA DERIVATIVES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MEDIVIR AB (SE) 2004-06-02 — — EP disclosed
WO-2004021969-A2 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MEDIVIR AB (SE) 2004-03-18 — — WO disclosed
US-6610714-B2 HIV viricides MEDIVIR AB (SE) 2003-08-26 — — US disclosed
US-20030092743-A1 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MEDIVIR AB (SE) 2003-05-15 — — US disclosed
WO-2003020705-A1 UREA AND THIOUREA DERIVATIVES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MEDIVIR AB (SE) 2003-03-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250136582-A1 SELECT KRAS G12C INHIBITORS AND USES THEREOF KRAS, NRAS, HRAS KDM4E 2375/4885ALDH1A1 2711/4885GLA 1903/4885
US-12617880-B2 Compounds for use in catalyst compositions for the production of polyolefins PRMT5, CBR3, MET KDM4E 1536/4885ALDH1A1 1762/4885GLA 3041/4885
US-20240254140-A1 COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION C3AR1, LTB4R, C5 KDM4E 4227/4885ALDH1A1 681/4885GLA 695/4885
US-20030092743-A1 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS SUB1, HCFC1, CCR1 KDM4E 960/4885ALDH1A1 848/4885GLA 2568/4885
US-20060167055-A1 Non-nucleoside reverse transcriptase inhibitors POLR2H, POLR2E, POLR1E KDM4E 2439/4885ALDH1A1 2705/4885GLA 3186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.